SEC Form 4 · accession 0001140361-16-090197
CYTRX CORP · CYTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas Scott Wieland
Officer — Sr VP - Drug Development
Period of report
Dec 15, 2016
Accepted (ET)
Dec 19, 2016 · 2:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000799698
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.43 | Dec 15, 2016 | A | 150,000 | A | — | Dec 14, 2026 | CytRx Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1The stock option vests monthly for 36 months in equal installments, beginning 15 January 2017, provided Reporting Person remains in continuous employ of Issuer, or the conditions for immediate vesting do not occur.